Meningococcal serogroup Y emergence in Europe: Update 2011

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1907-1911

  Bröker, Michael ^a   Jacobsson, Susanne ^b   Kuusi, Markku ^c   Pace, David ^d   Simões, Maria J ^e   Skoczynska, Anna ^f   Taha, Muhamed Kheir ^g   Toropainen, Maija ^c   Tzanakaki, Georgina ^h  

^a Novartis Vaccines and Diagnostics GmbH   (Germany)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d MATER DEI HOSPITAL   (Malta)

^e NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^f NATIONAL MEDICINES INSTITUTE   (Poland)

^g INSTITUT PASTEUR   (France)

^h NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

Epidemiology; Europe; Meningococcal disease; Serogroup Y; Surveillance

Indexed keywords

BACTERIAL ANTIGEN; MENINGOCOCCUS VACCINE;

BACTERIAL GENOME; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; DISEASE SURVEILLANCE; DRUG TARGETING; EUROPE; GENETIC DIFFERENCE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; INVASIVE MENINGOCOCCAL DISEASE; LUNG INFECTION; MENINGOCOCCEMIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NOTE; PHENOTYPE; PREVENTIVE MEDICINE; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; PYROSEQUENCING; VACCINATION;

EPIDEMIOLOGY; EUROPE; MENINGOCOCCAL DISEASE; SEROGROUP Y; SURVEILLANCE;

ADOLESCENT; ADULT; COMMUNICABLE DISEASES, EMERGING; EUROPE; FEMALE; HUMANS; INCIDENCE; MALE; MENINGITIS, MENINGOCOCCAL; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP Y; YOUNG ADULT;

EID: 84872232701     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21794     Document Type: Note

References (24)

1. Bröker M, Jacobsson S, Detora L, Pace D, Taha M-K. Increase of meningococcal serogroup Y cases in Europe: A reason for concern? Hum Vaccin Immunother 2012; 8:685-8; PMID:22508411; http://dx.doi.org/10.4161/hv.20098.
2. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196-210; PMID:17604802; http://dx.doi.org/10.1016/S0140-6736(07)61016-2.
3. Leimkugel J, Racloz V, Jacintho da Silva L, Pluschke G. Global review of meningococcal disease. A shifting etiology. J Bacterial Res 2009; 1:6-18.4.
4. Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era - United States, 2000-2005. J Infect Dis 2010; 201:1208-24; PMID:20199241; http://dx.doi.org/10. 1086/651505.
5. Pace D, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. Curr Opin Mol Ther 2009; 11:692-706; PMID:20072946.
6. Boisier P, Nicolas P, Djibo S, Taha M-K, Jeanne I, Maïnassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44:657-63; PMID:17278055; http://dx.doi.org/10.1086/511646.
7. European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report 2011. Invasive meningococcal disease, available at http://ecdc.europa.eu, assessed 25. 05. 2012
8. Sáfadi MAP, McIntosh EDG. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Rev Vaccines 2011; 10:1717-30; PMID:22085175; http://dx.doi.org/10.1586/erv.11.159.
9. Richmond PC, Marshall HS, Nissen MD, Jiang QJ, Jansen KU, Garcés-Sánchez M. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet 2012; 12:597-607; http://dx.doi.org/10.1016/S1473-3099(12)70087-7.
10. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617-24; PMID:22260988; http://dx.doi.org/10.1016/S0140-6736(11)61713-3.
11. Wassil J, McIntosh EDG, Serruto D, DeTora L, Bröker M, Kimura A. The early clinical development of a multicomponent vaccine against meningococcal serogroup B. Clin Investig 2012; 2:503-17; http://dx.doi.org/10.4155/cli.12.41.
12. Pizza M, DeTora L, Wassil J. Advances in meningococcal vaccines. Clin Pract 2012; 91:101-17; http://dx.doi.org/10.2217/cpr.11.128.
13. Memish ZA, Shibl AM. Consensus building and recommendations based on the available epidemiology of meningococcal disease in Gulf Cooperation Council States. Travel Med Infect Dis 2011; 9:60-6; PMID:21345738; http://dx.doi.org/10. 1016/j.tmaid.2011.01.004.
14. Inés Agudelo C, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis 2008; 14:990-1; PMID:18507927; http://dx.doi.org/10.3201/eid1406.071357.
15. Chacón-Cruz E, Sánchez-Flores A, Volker ML, Rivas-Landeros RM. Persistent endemicity of invasive meningococcal disease in Northern Mexico: A severe, preventable and unresolved health problem. European Society for Pediatric Infectious Diseases Congress 2012, Thessaloniki, Greece, poster presentation.
16. European Union Invasive Bacterial Infections Surveillance (EU-IBIS) Network. Invasive Neisseria meningitidis in Europe 2006. Health Protection Agency, London 2006. Available from http://www.euibis.org
17. Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann 1991; 14:57-65, discussion 65-6; PMID:1812437.
18. Tsolia MN, Theodoridou M, Tzanakaki G, Vlachou V, Mostrou G, Stripeli F, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis 2006; 25:449-56; PMID:16773393; http://dx.doi.org/10.1007/ s10096-006-0155-6.
19. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-7; PMID:20219881; http://dx.doi.org/10.1128/CVI.00529-09.
20. Web pages of national Public institutes are not listed here, because many of them are in national languages, but not in English. Readers interested in appropriate link(s) are requested to approach the corresponding author.
21. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359-95; PMID:1889047.
22. Krauland MG, Dunning Hotopp JC, Riley DR, Daugherty SC, Marsh JW, Messonnier NE, et al. Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States. PLoS One 2012; 7:e35699; PMID:22558202.
23. Stoddard JJ, DeTora LM, Yeh MM, Bröker M, McIntosh EDG. Strategies for the prevention of meningitis. In: Wireko-Brobby G, ed. Meningitis. Rijeka, Croatia: Intech, 2012: 163-84.
24. Masuet-Aumatell C, Borrow R, Zuckerman JN. Quadrivalent meningococcal conjugated vaccine: a routine or selective vaccine in Europe? J Infect 2012; 65:193-6; PMID:22543314; http://dx.doi.org/10.1016/j.jinf.2012.04.008.